This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
Read Full Article on MarketWatchAI SUMMARY
# GLP-1 Drug Shows Weight Loss Maintenance, Boosting Viking Therapeutics Viking Therapeutics' experimental drug VK2735 demonstrated sustained weight loss maintenance in clinical trials with a once-monthly dosing schedule, positioning it as a potential competitor to Eli Lilly's Zepbound and driving significant gains in Viking's stock price. The dual GLP-1/GIP mechanism of VK2735 addresses a key market opportunity in the rapidly growing obesity treatment sector, where dosing convenience could become a competitive differentiator against existing competitors
MENTIONED STOCKS
More Top Stories News
Tax-free bond yields are in a sweet spot. Get in before it’s too late.
My plan to pay off $7,500 in credit-card debt can work for you
Millions will lose Medicaid once new work rules kick in. These groups will be hit the hardest.
‘It doesn’t seem fair’: I’m retired and have plenty of money. Why can’t I qualify for a retail credit card?
Princeton’s 15-year run as the nation’s top college is over. This is the new No. 1 school.
Content sourced from MarketWatch. Not financial advice.